The global market for ulcerated necrobiosis lipoidica management is set to witness substantial growth in the coming years, with an estimated market valuation of USD 4.4 billion in 2023. It is projected to reach USD 7.9 billion by 2033, expanding at a compound annual growth rate (CAGR) of 6.03% during the forecast period. The growth is primarily driven by innovations in diagnostic techniques, including magnetic resonance imaging (MRI), along with the increasing number of drug approvals and new treatment options emerging in the market.
Necrobiosis lipoidica, a rare skin condition associated with ulceration, has been a major focus for medical research and treatment development. As advanced diagnostic methods become more accessible, the ability to diagnose this condition early and accurately has significantly improved. This, in turn, is expected to accelerate the demand for effective treatments and interventions in the market.
One of the most prominent treatment approaches currently being adopted is photochemotherapy (PUVA therapy) and photodynamic therapy, which are expected to dominate the treatment landscape for ulcerated necrobiosis lipoidica. These therapies are gaining traction due to their efficacy in managing the condition, driving market growth further.
In addition, the global market is experiencing a surge in drug development and an increasing number of drugs undergoing clinical trials. This shift toward biological and technological advances in the treatment of ulcerated necrobiosis lipoidica will continue to play a crucial role in market expansion. The introduction of new drugs will not only improve treatment outcomes but also address the significant unmet needs in the market, including the lack of clinically proven treatments.
However, the market faces challenges, particularly the rising economic burden associated with ulcerated necrobiosis lipoidica treatment. The direct and indirect costs of long-term treatment and the absence of universally effective therapies highlight the need for innovative solutions. This gap presents significant opportunities for market players to develop new drugs aimed at addressing resistant bacteria and reducing treatment costs, thus paving the way for further growth.
Regulatory approvals will also play a key role in boosting market dynamics. A notable example is the approval of Baxdela (delafloxacin) by the United States Food and Drug Administration (FDA) in June 2017. Baxdela, a fluoroquinolone antibiotic, is used for severe bacterial skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), and is expected to provide a valuable therapeutic option for ulcerated necrobiosis lipoidica patients.
As the market continues to expand, ongoing developments in treatment and diagnostics, coupled with the growing demand for effective solutions, will drive the growth of the global ulcerated necrobiosis lipoidica management market, positioning it for significant advancements over the next decade.
Key Takeaways:
- North America is expected to dominate the industry while reaching market share of around 41% by end of the forecast period.
- The market in Asia Pacific is projected to account for 32.8% market share by end of the projected period.
- By treatment type, ‘UVA1 Phototherapy’ is projected to account for 31% market share by end of the forecast period.
- Hospitals are expected to dominate the market by distribution channel, with a market share of 71% by 2033.
“Development of new clinically proven and effective drugs coupled with increasing healthcare expenditure is going to drive the treat market of Ulcerated necrobiosis lipoidica in the forecast period”- Comments an FMI Analyst
Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!
Competitive Landscape:
The Ulcerated Necrobiosis Lipoidica Management Market is intensely competitive and consists of numerous key market players. These key players are developing novel delivery systems for treating ulcerated necrobiosis lipoidica. This is estimated to fuel Ulcerated Necrobiosis Lipoidica Management Market. The key players in this market are: Astellas Pharma, Vibcare Pharma, Pfizer, Manus Aktteva Biopharma LLP, Mylan Pharmaceuticals Inc., Upsher-Smith Laboratories, Novartis, Sanofi, Merck, GlaxoSmithKline.
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to strengthen their product portfolio. This is anticipated to fuel the global Ulcerated Necrobiosis Lipoidica Management Market.
- In June 2022, Basilea Pharmaceutica Ltd declared positive topline results for the Phase III ERADICATE study, evaluating ceftobiprole in treating adult patients with bacterial bloodstream infections caused by Staphylococcus aureus.
- In January 2022, Paladin Labs Inc., which is a subsidiary of Endo International PLC announced the launch of ‘Xydalba’ (dalbavancin for injection), a 30-minute intravenous therapy for chronic bacterial skin structure infections that can be administered as a single- or two-dose.
- On July 7, 2021, Melinta Therapeutics, a pharmaceutical company, announced about launch of its product ‘KIMYRSA’. This drug is a lipoglycopeptide antibiotic that offers a complete course of treatment for chronic bacterial skin and skin structure infections including ulcerated necrobiosis lipoidica. This drug is effective in a single dose of 1200mg injection.
Key Segments Profiled in the Ulcerated Necrobiosis Lipoidica Management Industry Survey:
By Treatment:
- Skin Grafting
- Photodynamic Therapy
- UVA1 Phototherapy
- Topical Psoralen-UVA Therapy
- Drugs
- Antimalarial Agents
- Antitubercular Agents
- Immunosuppressive Agents
- Hemorrheologic Agents
- Fumaric Acid Esters
- Calcineurin Inhibitors
- Corticosteroids
By End User:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐅𝐌𝐈’𝐬 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐎𝐧𝐠𝐨𝐢𝐧𝐠 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐃𝐨𝐦𝐚𝐢𝐧:
Specialty Control Plasma Industry
Self-urinary Infection Testing Industry
Antibacterial Haemostatic Gels Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube